MÜNSTER, Germany--(BUSINESS WIRE)--Sirbal Ltd., a pharmaceutical company specializing in developing herbal medicinal and cosmetic products based on traditional Chinese medicine, announced today that it has received a provisional safety report for SIRB-001 cream. This report paves the way for the company to commercialize and market an assortment of topical skin care products in Germany and most of the greater European Union.
SIRB-001 is the R&D name for a multi-herbal extract of Chinese herbs. Dermatological studies have clearly shown SIRB-001 to be safe and effective in caring for skin prone to multiple dermatological indications, including psoriasis, eczema, atopic dermatitis, scalp psoriasis, acne and seborrhea. Working with global pharmaceutical services provider Diapharm GmbH & Co. KG, Sirbal shall be able to market SIRB-001 cream-based cosmetic products in Europe, once a manufacturer has been selected.
“We are pleased to be able to offer care based on SIRB-001 to consumers as a safe herbal-based alternative for stressed skin,” said Sirbal Founder & CEO, Nadav Shraibom. “The regulatory and strategic advice we received from Diapharm was an important step for Sirbal to seek commercialization partners for immediate product/SIRB-001 distribution.”
“Diapharm applauds Sirbal for undertaking a rigorous clinical review for its broad line of product,” said Ralf Sibbing, General Manager & Partner, Diapharm GmbH.
“The dermatological market is significant,” said James Bennett, Director at SNS Research. “It is estimated that the overall 2017 addressable market size for SIRB-001 products in Europe alone exceeds $6 billion USD with a roughly 5% CAGR for the next 5 years.”
Sirbal Ltd. was founded by Mr. Nadav Shraibom, a Chinese Herbal Medicine Clinician, with Messrs. Tal Dilian and Eran Steinberg as co-founders. Its mission is to provide safe and efficient treatments for inflammatory diseases. Its first products based on a multi-herbal botanical extract, SIRB-001, show clear efficacy in topical care of the skin prone to multiple dermatological indications. For additional background information, please refer to http://www.sirbal.com/background.
Contact for Commercialization and Partnering Opportunities:
Biotech Alliances International
(650) 868-8511 / email@example.com